Increasing minority participation in cancer clinical trials

Health University of California: Moon Chen, UC Davis, February 15, 2012.

UC Davis cancer center among five nationwide sites focused on recruitment, retention of minorities in clinical trials.

Researchers from the UC Davis Cancer Center are part of a national effort that has just received a five-year round of funding to better understand and address barriers that limit the participation of minority populations in cancer therapeutic trials.

The National Institute of Minority Health and Health Disparities (NIMHD), the newest of the National Institutes of Health institutes, has awarded a $5.1 million grant over five years to Enhancing Minority Participation in Clinical Trials (EMPaCT), a consortium of five institutions seeking to increase representation of multiple minority groups in cancer trials. The Phase II funding follows up on an earlier 18-month start-up Phase I grant.

EMPaCT consists of five National Cancer Institute-designated cancer centers and NIMHD disparities research program sites selected for their commitment to cancer and health disparities research, as well as cancer clinical trial development and implementation. In addition to UC Davis, which is representing the West region and focusing on Asian American accrual, participating institutions are:

  • University of Minnesota, Minneapolis, lead institution (Midwest — Native American and African American accrual)
  • University of Alabama, Birmingham, co-lead institution (Southeast — African American accrual)
  • Johns Hopkins University (East — African American accrual)
  • University of Texas M.D. Anderson in Houston (Southwest — Latino/Hispanic accrual)

The consortium’s Phase II goal is increasing the recruitment and retention of racial/ethnic minorities into therapeutic clinical trials to reduce cancer-related health disparities. The objective is to realize a 5 percent increase in participants over the next five years. Read Full Article